Thomas A Kirkland (Wytske M van Weerden, Wytske M Van Weerden)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 28

Top Topics

Locally Advanced

Cell Cycle Arrest

Radical Prostatectomy

Endoplasmic Reticulum Stress

Top Venues

British journal of cancer

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Mitchell G Lawrence, Renea A Taylor, Georgia B Cuffe, Lisa S Ang, Ashlee K Clark, David L Goode, Laura H Porter, Clémentine Le Magnen, Nora M Navone, Jack A Schalken, Yuzhuo Z Wang, Thomas A Kirkland, Eva Corey, John T Isaacs, Peter S Nelson, Gail P Risbridger
The future of patient-derived xenografts in prostate cancer research. Nature reviews. Urology (2023)
Stefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder, Debra Stuurman, Sigrun Erkens-Schulze, Sem Van 't Geloof, Wilma J Teubel, Stijn L W Koolen, Elena S Martens-Uzunova, Martin E van Royen, Ronald de Wit, Ron H J Mathijssen, Thomas A Kirkland
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition. Molecular cancer therapeutics (2023)
Annelies Van Hemelryk, Sigrun Erkens-Schulze, Lifani Lim, Corrina M A de Ridder, Debra C Stuurman, Guido W Jenster, Martin E van Royen, Thomas A Kirkland
Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids. Cells 12 (10) (2023)
Hildert Bronkhorst, Thomas A Kirkland, Eline Maria Bunnik, H A E Hub Zwart
Awe and anxiety for cancer cells: connecting scientists and patients in a holistic approach of metastasis research. Research involvement and engagement 9 (1) (2023)
Annelies Van Hemelryk, Ingrid Tomljanovic, Corrina M A de Ridder, Debra C Stuurman, Wilma J Teubel, Sigrun Erkens-Schulze, Esther I Verhoef, Sebastiaan Remmers, Amrish J Mahes, G J L H Geert van Leenders, Martin E van Royen, Harmen J G van de Werken, Magda Grudniewska, Guido W Jenster, Thomas A Kirkland
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling. Cells 11 (22) (2022)
Eline A M Ruigrok, Nicole S Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J Roobol, Dik C van Gent, Marion de Jong, Thomas A Kirkland, Julie Nonnekens
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. International journal of molecular sciences 23 (14) (2022)
J Matthijs Moll, Johannes Hofland, Wilma J Teubel, Corina M A de Ridder, Angela E Taylor, Ralph Graeser, Wiebke Arlt, Guido W Jenster, Thomas A Kirkland
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. The Prostate 82 (5) (2022)
Gido Snaterse, Rosinda Mies, Thomas A Kirkland, Pim J French, Johan W Jonker, Adriaan B Houtsmuller, Martin E van Royen, Jenny A Visser, Johannes Hofland
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate cancer and prostatic diseases (2022)
Rosalba Mansi, Berthold A Nock, Simone U Dalm, Martijn B Busstra, Thomas A Kirkland, Theodosia Maina
Radiolabeled Bombesin Analogs. Cancers 13 (22) (2021)
Sanjiban Chakrabarty, William F Quiros-Solano, Maayke Mp Kuijten, Ben Haspels, Sandeep Mallya, Calvin Shun Yu Lo, Amr Othman, Cinzia Silvestri, Anja van de Stolpe, Nikolas Gaio, Hanny Odijk, Marieke van de Ven, Corrina M A de Ridder, Thomas A Kirkland, Jos Jonkers, Ronald Dekker, Nitika Taneja, Roland Kanaar, Dik C van Gent
A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture. Cancer research (2021)
Annelies Van Hemelryk, Lisanne Mout, Sigrun Erkens-Schulze, Pim J French, Thomas A Kirkland, Martin E van Royen
Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Biomolecules 11 (11) (2021)
Arjanneke F van de Merbel, Geertje van der Horst, Maaike H van der Mark, Selas T F Bots, Diana J M van den Wollenberg, Corrina M A de Ridder, Debra Stuurman, Tilly Aalders, Sigrun Erkens-Schulz, Nadine van Montfoort, Wouter R Karthaus, Niven Mehra, Minke Smits, Jack A Schalken, Thomas A Kirkland, Wytske M van Weerden, Gabri van der Pluijm
Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. Cancer gene therapy (2021)
Thomas A Kirkland
Patient-Derived Xenograft Models in Cancer Research. Cancers 13 (4) (2021)
Lisanne Mout, Jan M Moll, Mingqing Chen, Eleonora S de Morrée, Corrina M A de Ridder, Alice Gibson, Debra Stuurman, Ashraf Aghai, Sigrun Erkens-Schulze, Ron H J Mathijssen, Alex Sparreboom, Ronald de Wit, Martijn Paul Lolkema, Thomas A Kirkland
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. British journal of cancer 123 (12) (2020)
Natasa Gaspar, Giorgia Zambito, Iris J C Dautzenberg, Steve J Cramer, Rob C Hoeben, Thomas A Kirkland, Joel R Walker, Thomas A Kirkland, Clemens W G M Löwik, Wytske M van Weerden, Jeroen de Vrij, Laura Mezzanotte
NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice-A Novel in Vivo Imaging Platform. International journal of molecular sciences 21 (16) (2020)
Stanislav Drápela, Prashant Khirsariya, Thomas A Kirkland, Radek Fedr, Tereza Suchánková, Diana Búzová, Jan Cerveny, Aleš Hampl, Martin Puhr, William R Watson, Zoran Culig, Lumír Krejčí, Kamil Paruch, Karel Souček
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology 14 (10) (2020)
Wenhao Zhang, Chen-Yi Liao, Hajar Chtatou, Luca Incrocci, Dik C van Gent, Thomas A Kirkland, Julie Nonnekens
Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair. Cancers 11 (10) (2019)
Eline A M Ruigrok, Thomas A Kirkland, Julie Nonnekens, Marion de Jong
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research. Pharmaceutics 11 (11) (2019)
J Matthijs Moll, Jinpei Kumagai, Martin E van Royen, Wilma J Teubel, Robert J van Soest, Pim J French, Yukio Homma, Guido Jenster, Ronald de Wit, Thomas A Kirkland
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. The Prostate 79 (9) (2019)
Petra W van Duijn, Rute B Marques, Angelique C J Ziel-van der Made, Hanneke J A A van Zoggel, Ashraf Aghai, Cor Berrevoets, Reno Debets, Guido Jenster, Jan Trapman, Thomas A Kirkland
Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model. The Prostate 78 (13) (2018)